Results 251 to 260 of about 32,890 (266)

Comparative Study Of The Effectiveness Of Vedolizumab Versus Ustekinumab After Anti-Tnf Failure In Crohn's Disease (Versus-Cd): Data From Eneida Registry.

Journal of Crohn's & Colitis, 2023
M. J. García, M. Rivero, A. Fernández-Clotet, R. de Francisco, B. Sicilia, F. Mesonero, M. D. de Castro, M. Casanova, F. Bertoletti, F. García-Alonso, A. López-García, R. Vicente, X. Calvet, M. Barreiro‐de Acosta, J. F. Ferrer Rosique, P. Varela Trastoy, Alejandro Núñez, E. Ricart, S. Riestra, L. Arias García, María Rodríguez, L. Arranz, R. Pajares, R. Mena, M. Calafat, P. Camo, F. Bermejo, Á. Ponferrada, R. Madrigal, J. Llaó, E. Sesé, E. Sánchez, J. R. Pineda Mariño, C. González Muñoza, Ana Yaiza Carbajo López, A. B. Julián, Albert Villoria Ferrer, I. Bastón-Rey, Lorena Jara, P. Almela, L. Codesido, S. de la Maza, C. Leal, B. Caballol, I. Pérez-Martínez, Raquel Vinuesa Campo, J. Crespo, E. Doménech, M. Chaparro, J. Gisbert   +49 more
semanticscholar   +1 more source

Ustekinumab for Refractory Colitis Associated with Immune Checkpoint Inhibitors

New England Journal of Medicine, 2021
Yinghong Wang
exaly  

Ustekinumab

Reactions Weekly, 2012
openaire   +1 more source

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Lancet, The, 2008
Ka Papp, Mark G Lebwohl, Kristian Reich
exaly  

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

Lancet, The, 2009
Alice B Gottlieb, Alan Menter, Arthur Kavanaugh   +2 more
exaly  

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Lancet, The, 2008
Alexa B Kimball, Ka Papp, Kenneth B Gordon   +2 more
exaly  

Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease

New England Journal of Medicine, 2012
Bruce E Sands, Subrata Ghosh, Remo Panaccione   +2 more
exaly  

STEP-CD study: ustekinumab use in paediatric Crohn’s disease—a multicentre retrospective study from paediatric IBD Porto group of ESPGHAN

European Journal of Pediatrics
G. Pujol-Muncunill, V. Navas‐López, O. Ledder, S. Cohen, Marina Lekar, Dan Turner, K. Kolho, Arie Levine, Nicholas M Croft, J. Bronský, D. Shouval, A. Assa, R. Harris, F. Kiparissi, M. Aloi, N. Afzal, C. Tzivinikos, J. Barrio, C. Norden, María Jesús Balboa Vega, S. Buderus, Ana Fernández de Valderrama, L. de Ridder, R. García-Romero, Enrique Medina, César Sánchez, Marta Velasco, S. Vicente, D.C Wilson, S. Naik, O. Hradsky, L. Cococcioni, J. Martín-de-Carpi   +32 more
semanticscholar   +1 more source

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Lancet, The, 2013
Arthur Kavanaugh, Luis Puig, Proton Rahman   +2 more
exaly  

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study

Lancet, The, 2018
Ronald F Van Vollenhoven, George C Tsokos, Peter E Lipsky   +2 more
exaly